With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.

The Glasgow-based group has raised more cash to take its new class of anti-infective through Phase IIa trials for C diff-associated disease.

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.